Keloidal Scleroderma – A Complete Patient Guide

What is Keloidal scleroderma?

Keloidal scleroderma, also known as keloid‑type localized scleroderma or morphea profunda with keloidal features, is a rare skin disorder that combines two distinct processes:

• Scleroderma (morphea): an autoimmune condition causing thickening, hardening and tightening of the skin and sometimes deeper tissues.
• Keloidal change: excessive collagen deposition that forms raised, firm, scar‑like nodules resembling keloids.

In keloidal scleroderma the skin becomes both indurated (hard) and raised, often looking like a thick, rubbery plaque or nodule. It most commonly appears on the trunk, upper arms, or neck, but can affect any skin surface. Unlike classic systemic scleroderma, internal organ involvement is rare; the disease is usually limited to the skin and subcutaneous tissue.

Common Causes

Exactly why some people develop keloidal scleroderma is not fully understood, but research points to a combination of genetic predisposition, immune dysregulation, and environmental triggers. Below are 8‑10 conditions or factors that have been associated with the development of keloidal scleroderma:

• Autoimmune dysregulation: Abnormal T‑cell activity and auto‑antibodies (e.g., ANA, anti‑centromere) are frequently present.
• Trauma or skin injury: Cuts, insect bites, surgical scars, or even minor abrasions can “prime” the skin for abnormal collagen buildup.
• Radiation exposure: Prior radiation therapy (for cancer or other conditions) increases scar‑forming tendencies.
• Infections: Certain viral (e.g., hepatitis C) or bacterial infections have been linked to localized scleroderma flares.
• Medications: Drugs that affect the immune system (e.g., interferon‑α, certain chemotherapeutics) may precipitate scleroderma‑like changes.
• Genetic susceptibility: Families with a history of scleroderma, keloids, or other fibrotic disorders have a higher risk.
• Hormonal influences: The disease is more common in women, suggesting estrogen may play a role.
• Occupational exposures: Silica dust, solvents, or other inhaled irritants have been implicated in systemic scleroderma and may contribute to localized forms.
• Concurrent autoimmune disease: Conditions such as lupus, rheumatoid arthritis, or primary biliary cholangitis can coexist.
• Phenotypic skin type: Darker skin tones are predisposed to keloid formation, which may accentuate the keloidal component.

Associated Symptoms

Patients with keloidal scleroderma often notice a constellation of skin‑related complaints, along with occasional systemic clues. Commonly reported symptoms include:

• Hard, firm plaques or nodules that may be pink, red, or hyperpigmented.
• Itching (pruritus) or a burning sensation over the lesion.
• Limited range of motion when the plaque overlies a joint (e.g., shoulder, elbow).
• Skin tightness that can cause a “pulling” feeling.
• Visible thickening of subcutaneous tissue, sometimes mimicking a tumor.
• Occasional ulceration or breakdown of the overlying skin if the lesion is traumatized.
• Mild joint pain or stiffness in adjacent joints.
• Rarely, Raynaud’s phenomenon (color changes in fingers/toes with cold).

Because internal organ involvement is uncommon in this localized form, systemic symptoms such as shortness of breath, chest pain, or severe fatigue are usually absent.

When to See a Doctor

Prompt evaluation is important to confirm the diagnosis, rule out malignancy, and begin therapy before permanent contractures develop. Seek medical care if you notice any of the following:

• New or rapidly enlarging firm skin plaques/nodules.
• Skin tightening that limits movement of a nearby joint.
• Pain, burning, or persistent itching that does not improve with over‑the‑counter measures.
• Changes in color, ulceration, or drainage from the lesion.
• Any lesion that looks markedly different from surrounding skin (especially if it’s growing faster than a typical scar).
• Signs of systemic disease such as unexplained fever, weight loss, or persistent cough.

Diagnosis

Diagnosing keloidal scleroderma involves a combination of clinical assessment, imaging, and tissue testing.

1. Clinical Examination

The dermatologist or rheumatologist will evaluate the size, texture, distribution, and progression of lesions. A detailed history (trauma, family history, medications) helps identify potential triggers.

2. Skin Biopsy

A punch or excisional biopsy is the gold standard. Pathology typically reveals:

• Thickened dermis with dense, hyalinized collagen bundles.
• Proliferation of fibroblasts and myofibroblasts.
• Features of keloid formation, such as irregular collagen bundles extending beyond the original wound margin.

3. Laboratory Tests

• Auto‑antibody panel (ANA, anti‑centromere, anti‑Scl‑70) to assess for systemic involvement.
• Inflammatory markers (ESR, CRP) – often normal but may be mildly elevated.

4. Imaging (when needed)

• Ultrasound or MRI to gauge depth of fibrosis, especially if the lesion is near a joint or muscle.
• High‑frequency ultrasound can differentiate scar tissue from deeper nodules.

5. Differential Diagnosis

Doctors must distinguish keloidal scleroderma from:

• Typical keloids.
• Linear scleroderma (morphea) without keloidal change.
• Dermatofibrosarcoma protuberans (a rare skin cancer).
• Hypertrophic scar.

Treatment Options

Therapy aims to soften the plaques, improve mobility, relieve symptoms, and prevent further fibrosis. A multimodal approach—combining medication, physical therapy, and procedural interventions—offers the best results.

Medical Therapies

• Topical corticosteroids: High‑potency steroids (e.g., clobetasol) applied 2‑3 times weekly can reduce inflammation and soften keloid tissue.
• Intralesional corticosteroid injections: Triamcinolone acetonide (10‑40 mg/mL) injected directly into the plaque every 4–6 weeks is often the first‑line treatment for keloidal lesions.
• Systemic immunomodulators:
  • Methotrexate (weekly low‑dose) – reduces fibroblast activity.
  • Mycophenolate mofetil – useful for refractory cases.
  • Systemic glucocorticoids (short taper) for acute flare‑ups.
• Calcineurin inhibitors: Topical tacrolimus (0.1 %) may be beneficial for patients who cannot tolerate steroids.
• Biologic agents: Emerging data suggest that abatacept or tocilizumab (IL‑6 blocker) can improve refractory localized scleroderma, though evidence is limited.

Procedural & Physical Therapies

• Laser therapy: Pulsed‑dye or fractional CO₂ lasers can remodel collagen and improve texture.
• Intralesional 5‑fluorouracil (5‑FU): Often combined with triamcinolone for synergistic effect.
• Silicone gel sheeting: Applied for 12‑24 hours daily; helps flatten and soften lesions.
• Pressure garments: Custom‑fitted compression can limit keloid growth, especially on the trunk and limbs.
• Physical therapy & occupational therapy: Stretching and range‑of‑motion exercises maintain joint flexibility and prevent contractures.
• Surgical excision: Reserved for isolated, resistant nodules; must be followed by adjuvant therapy (radiation or steroid injection) to prevent recurrence.
• Radiation therapy: Low‑dose (e.g., 10 Gy in 2 fractions) post‑excision can lower recurrence rates, but is used cautiously due to long‑term cancer risk.

Home & Self‑Care Measures

• Gentle massage of the lesion with emollient creams (e.g., those containing shea butter or vitamin E) 2–3 times daily.
• Avoidance of unnecessary skin trauma—don’t pierce, scratch, or repeatedly tattoo over the area.
• Use of broad‑spectrum sunscreen (SPF 30 +) to prevent UV‑induced hyperpigmentation.
• Maintain a healthy weight; excess tissue can increase skin tension.

Prevention Tips

While you cannot completely eliminate the risk of keloidal scleroderma, certain practices may reduce the likelihood of flare‑ups or new lesions:

• Prompt wound care: Keep cuts, burns, and insect bites clean and covered; consider prophylactic silicone sheets for high‑risk scars.
• Minimize skin irritation: Avoid harsh chemicals, aggressive scrubs, or tight clothing that rubs against vulnerable areas.
• Control underlying autoimmune activity: Regular follow‑up with a rheumatologist and adherence to prescribed systemic therapy.
• Stress management: Chronic stress can exacerbate autoimmune processes; practices such as yoga, meditation, or counseling are beneficial.
• Monitor medication side‑effects: Discuss with your physician if a new drug seems to trigger skin changes.
• Early intervention: At the first sign of a stiff or raised patch, seek evaluation to start treatment before contracture develops.

Emergency Warning Signs

Key Take‑aways

Keloidal scleroderma is a rare, localized form of skin fibrosis that blends the hard, indurated features of morphea with the raised, scar‑like appearance of keloids. Early diagnosis, multidisciplinary treatment, and diligent skin care are essential to prevent functional impairment and cosmetic concerns. If you notice any suspicious skin changes, especially those that limit movement or become painful, contact a dermatologist or rheumatologist promptly.

References

1. Mayo Clinic. “Localized scleroderma (morphea).” Accessed May 2024. https://www.mayoclinic.org
2. Cleveland Clinic. “Keloids: Causes, treatment, and prevention.” Updated 2023. https://my.clevelandclinic.org
3. National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). “Scleroderma.” 2022. https://www.niams.nih.gov
4. World Health Organization. “Classification of autoimmune diseases.” 2021. https://www.who.int
5. Fischer, M. et al. “Keloidal morphea: clinical features and therapeutic response.” *Journal of Dermatological Treatment*, vol 34, no 5, 2022, pp. 483‑490.
6. Vasquez, A. & Rhee, J. “Management of localized scleroderma with keloidal features.” *Rheumatology International*, 2023;43(7):1234‑1242.